Medtronic breaks ground on western China Innovation Center
Medtronic (NYSE:MDT) said today it has begun work on an Innovation Center in Chengdu, China, slated to open in 2020. The new Chengdu Innovation Center is being built at the Singapore-Sichuan Hi-Tech Innovation Park in the Sichuan Province and aims to provide clinical training and research platforms for medical workers in the region and neighboring regions. “Medtronic understands the critical role that rural physicians play in driving the healthcare availability and transformation. As such, we hope to support the growth and development of medical workers in China’s vast central and western regions, help them better understand, grasp and capitalize the frontier technologies, enhance their clinical skills to benefit more patients, and move forward together toward the Healthy China goal,” Medtronic CEO Omar Ishrak said in a prepared statement. Medtronic said that despite improved clinical training investments, training in China’s western regions “remains insufficient” and has created an average 10-year gap between the maturation period of Chinese physicians and those in developed countries. “Chengdu is actively fostering innovation within the biopharmaceutical industry, and it’s particularly important to build an open and pragmatic innovation environment. We hope that more international leading platforms, like the Medtronic Innovation Center, can inspire innovation and become a driving force in helping us explore loca...
Conclusions Percutaneous transabdominal embolization is a safe and efficacious treatment for type II endoleak, with a short procedure time.
Retrospective analysis of a single-center experience.
Longitudinal study of patients entered at baseline between 1987 and 1989 in the Atherosclerosis Risk in Communities (ARIC) study from four U.S. communities in Mississippi, Maryland, Minnesota, and North Carolina.
Whereas the early mortality benefit of endovascular aneurysm repair (EVAR) over open repair for intact abdominal aortic aneurysms (AAAs) has been confirmed in numerous randomized trials and observational studies, the data regarding outcomes after repair of ruptured AAAs (rAAAs) are conflicting. As summarized in a recent Cochrane review, four randomized controlled trials failed to demonstrate improved short-term mortality after EVAR for rAAA.1 However, these trials were limited by small sample size, inclusion criteria leading to the exclusion of many patients, and frequent treatment variation from randomization.
This study's objective was to evaluate coding accuracy and its effect on hospital cost for patients undergoing EVAR.
The objective of this study was to assess outcomes of a hybrid technique for treatment of abdominal aortic aneurysm (AAA) associated with iliac aneurysm without distal neck by combining an AAA endovascular repair approach with open surgery for preservation of the internal iliac artery (IIA).
Strijbos et al. found that some 75% of patients with peripheral arterial disease (PAD) or an abdominal aortic aneurysm (AAA) have inadequate health literacy (HL), meaning that they are not able to obtain, process, or understand medical information adequately.1 This is a very important finding for all professi onals who treat patients with arterial disease. One might of course question the validity of the Newest Vital Sign (NVS) Dutch version and wonder how one can accurately measure HL using the nutritional information on an ice cream wrapping.
Abdominal aortic aneurysm (AAA) is three to five times more common among men compared with women, yet up to 38% of all aneurysm related deaths affect women. The aim of this study was to estimate the prevalence of synchronous or metachronous aneurysms among women with AAA, as diagnosis and treatment could improve survival.
Regulators say the company's AFX endovascular graft system with Strata material -- used for abdominal aortic aneurysm repair -- is at greater risk for type III endoleaks compared with other devices for the same indication.News Alerts
Conclusions The prevalence of undiagnosed AAA in patients older than 50 years hospitalised in internal medicine was 2.9%. The data lead us to recommend AAA screening for this population of male patients with a history of smoking and an ABI<0.9. Clinical ultrasonography enables this screening in a reliable manner.
More News: Abdominal Aortic Aneurysm | Academia | Aortic Aneurysm | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | China Health | Environmental Health | Gastroenterology | Heart | Intensive Care | Internal Medicine | Minimally Invasive Surgery | Respiratory Medicine | Rural Health | Singapore Health | Training | Universities & Medical Training